Nigeria’s ambitious push to curb cervical cancer has reached a scale few countries have matched. Since October 2023, more than 13 million girls have been vaccinated against the human papillomavirus (HPV), marking one of the largest HPV immunisation campaigns globally and a major public health milestone for Africa’s most populous nation.
Health authorities and international partners have rightly celebrated the achievement as a breakthrough in cancer prevention. Yet beneath the impressive numbers lies a quieter, more complex question: does the vaccine at the heart of this historic rollout fully protect Nigerian girls against the HPV strains most responsible for cervical cancer in the country?
The national campaign has been rolled out with optimism and political backing, but experts argue that scale alone should not be the sole measure of success. As Nigeria commits vast resources to prevention, attention is turning to whether the intervention aligns closely enough with local disease patterns. Emerging research from Nigeria and the wider West African region suggests there may be a gap between the vaccine used and the HPV strains most prevalent among Nigerian women—a gap that could shape cancer outcomes years from now.
Nigeria is currently deploying the quadrivalent Gardasil vaccine, which protects against HPV types 6, 11, 16 and 18. Worldwide, types 16 and 18 are responsible for roughly 70–76% of cervical cancer cases, a statistic that has driven the global adoption of vaccines targeting these strains. On that basis, Gardasil remains an effective and life-saving tool.
However, studies conducted in Nigeria and neighbouring countries indicate that other high-risk HPV types—particularly 35, 45, 52 and 58—may play a more prominent role in cervical cancer locally than global averages suggest. While types 16 and 18 are still significant contributors, the regional data point to a more diverse strain profile. Nationally representative cancer-attribution data remain limited, but the available evidence has been enough to prompt concern among researchers and clinicians.
This does not diminish the value of Nigeria’s vaccination programme, which is already preventing countless future infections. It does, however, raise the issue of whether protection could be stronger. A broader vaccine, Gardasil-9, covers nine HPV types, including several that appear more common in West Africa. Yet Gardasil-9 is largely unavailable in Nigeria, constrained by higher costs and limited global supply.
The implications are not abstract. If certain cancer-causing strains are under-covered, fully vaccinated girls may still face a measurable risk of developing cervical cancer later in life. Nigeria could be running a prevention campaign of unprecedented scale using a vaccine that, while effective, does not fully reflect local HPV epidemiology.
Cost and availability largely explain this mismatch. Gardasil-9 is significantly more expensive, and manufacturers struggle to meet global demand. For a country vaccinating millions of girls, these constraints are real. But public health experts argue they should not end the discussion. Nigeria bears one of the world’s heaviest cervical cancer burdens, with an estimated 12,000 new cases and 8,000 deaths each year. A strategy that mirrors the country’s actual disease profile may be essential if those numbers are to fall meaningfully.
Any shortcomings in vaccine coverage will not become visible quickly. HPV-related cancers often take decades to develop, meaning the true impact of today’s choices may only be apparent years from now. By then, an entire generation may have passed through the programme without the option of broader protection.
Supporters of the current approach note—correctly—that some protection is far better than none. Gardasil is estimated to prevent about 70% of cervical cancers globally, and that benefit remains substantial. Still, in a context where other HPV strains appear more prevalent, that level of protection may be lower in practice. When millions of girls are involved, the difference between “substantial” and “optimal” becomes consequential.
The debate also highlights a broader challenge in global health. Interventions developed and tested primarily in high-income settings are often transferred to low- and middle-income countries with limited adaptation. Cervical cancer, however, does not follow a uniform global pattern. HPV strain distribution varies by region, and prevention strategies are most effective when tailored to local realities.
Policy experts point to several priorities. Securing access to Gardasil-9 or other broader-spectrum vaccines would be a critical step, potentially through negotiated pricing or expanded donor support. At the same time, Nigeria needs stronger local data. Expanded research and a national HPV surveillance programme could provide the evidence base needed to refine vaccination policy.
Vaccination alone will also not be enough. Screening remains essential, yet Nigeria’s cervical cancer screening services are still limited, unevenly distributed and largely urban. Without accessible screening, cases caused by vaccine-covered and non-covered strains alike will continue to be detected late, when treatment is more difficult and survival rates are lower.
Social barriers persist as well. Parental resistance, driven by fears that HPV vaccination promotes early sexual activity, continues to limit uptake. Because girls aged 9 to 12 require parental consent, community engagement and public education will be crucial if Nigeria hopes to meet the World Health Organization’s target of vaccinating 90% of girls by age 15.
Nigeria’s HPV vaccination drive represents a bold and commendable commitment to women’s health. But ambition must be matched with precision. Thirteen million vaccinations are an extraordinary start; ensuring that those vaccinations offer the strongest possible protection will determine whether the programme ultimately delivers on its promise.
Cervical cancer is largely preventable, and no Nigerian woman should die from a disease science already knows how to stop. Achieving that goal will require not just scale, but alignment—between vaccines, local epidemiology and the long-term realities of cancer prevention.
Oluwadara Alegbeleye is an environmental and food microbiologist, science writer, and consultant.
Dr Oluwatosin Dongo, (MBBS), is a speciality registrar in general practice.